The Manila Times40m
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
As of December 31, 2024, the Company had cash and cash equivalents in the amount of $15.6 million, compared to $5.3 million ...
The Manila Times41m
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...